APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ankylosing Spondylitis Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Ankylosing Spondylitis Treatment Drug Market Analysis and Forecast 2026-2032

31 December 2025208 pages

Choose your research edition.

Industry ResearchAnkylosing Spondylitis Treatment Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Ankylosing Spondylitis Treatment Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Ankylosing Spondylitis Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ankylosing Spondylitis Treatment Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Ankylosing Spondylitis Treatment Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Ankylosing Spondylitis Treatment Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Ankylosing Spondylitis Treatment Drug include UCB, Abbott, Takeda, Eisai, Guojian Pharmaceutical, Celgen Pharm, Johson & Johson, Novartis and Merck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ankylosing Spondylitis Treatment Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ankylosing Spondylitis Treatment Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Ankylosing Spondylitis Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ankylosing Spondylitis Treatment Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ankylosing Spondylitis Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Ankylosing Spondylitis Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.

Ankylosing Spondylitis Treatment Drug Segment by Company

UCB

Abbott

Takeda

Eisai

Guojian Pharmaceutical

Celgen Pharm

Johson & Johson

Novartis

Merck

Maibo Pharma

Pfizer

Hisun Pharm

Bio-Thera Solutions

Amgen

Abbive

Mitsubishi Tanabe

Ankylosing Spondylitis Treatment Drug Segment by Type

Non-steroidal Anti-inflammatory Drugs

Inhibitor

Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Other

Ankylosing Spondylitis Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ankylosing Spondylitis Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ankylosing Spondylitis Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ankylosing Spondylitis Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Ankylosing Spondylitis Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Ankylosing Spondylitis Treatment Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ankylosing Spondylitis Treatment Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ankylosing Spondylitis Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Non-steroidal Anti-inflammatory Drugs Major Player Table 3. Inhibitor Major Player Table 4. Global Ankylosing Spondylitis Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Retail Pharmacy Major Player Table 6. Online Pharmacy Major Player Table 7. Hospital Pharmacy Major Player Table 8. Other Major Player Table 9. Ankylosing Spondylitis Treatment Drug Industry Trends Table 10. Ankylosing Spondylitis Treatment Drug Industry Drivers Table 11. Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges Table 12. Ankylosing Spondylitis Treatment Drug Industry Restraints Table 13. Global Ankylosing Spondylitis Treatment Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Ankylosing Spondylitis Treatment Drug Market Share by Region (2021-2026) Table 16. Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Ankylosing Spondylitis Treatment Drug Market Share by Region (2027-2032) Table 18. Global Ankylosing Spondylitis Treatment Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Players (2021-2026) Table 20. Global Ankylosing Spondylitis Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Ankylosing Spondylitis Treatment Drug Key Players Headquarters & Area Served Table 22. Global Ankylosing Spondylitis Treatment Drug Players, Product Type & Application Table 23. Global Ankylosing Spondylitis Treatment Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Ankylosing Spondylitis Treatment Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Ankylosing Spondylitis Treatment Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Type (2021-2026) Table 30. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Type (2027-2032) Table 31. Global Ankylosing Spondylitis Treatment Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2021-2026) Table 35. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2027-2032) Table 36. UCB Company Information Table 37. UCB Business Overview Table 38. UCB Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. UCB Ankylosing Spondylitis Treatment Drug Product Portfolio Table 40. UCB Recent Development Table 41. Abbott Company Information Table 42. Abbott Business Overview Table 43. Abbott Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio Table 45. Abbott Recent Development Table 46. Takeda Company Information Table 47. Takeda Business Overview Table 48. Takeda Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio Table 50. Takeda Recent Development Table 51. Eisai Company Information Table 52. Eisai Business Overview Table 53. Eisai Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio Table 55. Eisai Recent Development Table 56. Guojian Pharmaceutical Company Information Table 57. Guojian Pharmaceutical Business Overview Table 58. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio Table 60. Guojian Pharmaceutical Recent Development Table 61. Celgen Pharm Company Information Table 62. Celgen Pharm Business Overview Table 63. Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 65. Celgen Pharm Recent Development Table 66. Johson & Johson Company Information Table 67. Johson & Johson Business Overview Table 68. Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio Table 70. Johson & Johson Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio Table 75. Novartis Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Merck Ankylosing Spondylitis Treatment Drug Product Portfolio Table 80. Merck Recent Development Table 81. Maibo Pharma Company Information Table 82. Maibo Pharma Business Overview Table 83. Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio Table 85. Maibo Pharma Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio Table 90. Pfizer Recent Development Table 91. Hisun Pharm Company Information Table 92. Hisun Pharm Business Overview Table 93. Hisun Pharm Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio Table 95. Hisun Pharm Recent Development Table 96. Bio-Thera Solutions Company Information Table 97. Bio-Thera Solutions Business Overview Table 98. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio Table 100. Bio-Thera Solutions Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio Table 105. Amgen Recent Development Table 106. Abbive Company Information Table 107. Abbive Business Overview Table 108. Abbive Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio Table 110. Abbive Recent Development Table 111. Mitsubishi Tanabe Company Information Table 112. Mitsubishi Tanabe Business Overview Table 113. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio Table 115. Mitsubishi Tanabe Recent Development Table 116. North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Ankylosing Spondylitis Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 130. China Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 131. China Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 132. China Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 133. China Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Ankylosing Spondylitis Treatment Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Ankylosing Spondylitis Treatment Drug Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Ankylosing Spondylitis Treatment Drug Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Ankylosing Spondylitis Treatment Drug Image Figure 2. Global Ankylosing Spondylitis Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ankylosing Spondylitis Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Non-steroidal Anti-inflammatory Drugs Image Figure 5. Inhibitor Image Figure 6. Global Ankylosing Spondylitis Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Ankylosing Spondylitis Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Retail Pharmacy Image Figure 9. Online Pharmacy Image Figure 10. Hospital Pharmacy Image Figure 11. Other Image Figure 12. Global Ankylosing Spondylitis Treatment Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Ankylosing Spondylitis Treatment Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Ankylosing Spondylitis Treatment Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Ankylosing Spondylitis Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032) Figure 25. North America Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032) Figure 26. North America Ankylosing Spondylitis Treatment Drug Revenue Share by Country (2021-2032) Figure 27. United States Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032) Figure 32. Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032) Figure 33. Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Country (2021-2032) Figure 34. Germany Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032) Figure 44. China Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032) Figure 45. Asia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032) Figure 47. Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032) Figure 48. Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Region (2021-2032) Figure 49. Japan Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Ankylosing Spondylitis Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Non-steroidal Anti-inflammatory Drugs
  • Inhibitor
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Other
Companies covered
  • UCB
  • Abbott
  • Takeda
  • Eisai
  • Guojian Pharmaceutical
  • Celgen Pharm
  • Johson & Johson
  • Novartis
  • Merck
  • Maibo Pharma
  • Pfizer
  • Hisun Pharm
  • Bio-Thera Solutions
  • Amgen
  • Abbive
  • Mitsubishi Tanabe

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ankylosing Spondylitis Treatment Drug Market by Type
  3. 1.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Non-steroidal Anti-inflammatory Drugs
  5. 1.2.3 Inhibitor
  6. 1.3 Ankylosing Spondylitis Treatment Drug Market by Application
  7. 1.3.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacy
  9. 1.3.3 Online Pharmacy
  10. 1.3.4 Hospital Pharmacy
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Ankylosing Spondylitis Treatment Drug Market Dynamics
  1. 2.1 Ankylosing Spondylitis Treatment Drug Industry Trends
  2. 2.2 Ankylosing Spondylitis Treatment Drug Industry Drivers
  3. 2.3 Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Ankylosing Spondylitis Treatment Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Ankylosing Spondylitis Treatment Drug Market Perspective (2021-2032)
  2. 3.2 Global Ankylosing Spondylitis Treatment Drug Growth Trends by Region
  3. 3.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Players
  2. 4.1.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Ankylosing Spondylitis Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ankylosing Spondylitis Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Ankylosing Spondylitis Treatment Drug Key Players Headquarters & Area Served
  7. 4.4 Global Ankylosing Spondylitis Treatment Drug Players, Product Type & Application
  8. 4.5 Global Ankylosing Spondylitis Treatment Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Ankylosing Spondylitis Treatment Drug Market CR5 and HHI
  11. 4.6.3 2025 Ankylosing Spondylitis Treatment Drug Tier 1, Tier 2, and Tier 3
5 Ankylosing Spondylitis Treatment Drug Market Size by Type
  1. 5.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 5.3 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Type (2021-2032)
6 Ankylosing Spondylitis Treatment Drug Market Size by Application
  1. 6.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  3. 6.3 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 UCB
  2. 7.1.1 UCB Company Information
  3. 7.1.2 UCB Business Overview
  4. 7.1.3 UCB Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 UCB Ankylosing Spondylitis Treatment Drug Product Portfolio
  6. 7.1.5 UCB Recent Developments
  7. 7.2 Abbott
  8. 7.2.1 Abbott Company Information
  9. 7.2.2 Abbott Business Overview
  10. 7.2.3 Abbott Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio
  12. 7.2.5 Abbott Recent Developments
  13. 7.3 Takeda
  14. 7.3.1 Takeda Company Information
  15. 7.3.2 Takeda Business Overview
  16. 7.3.3 Takeda Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio
  18. 7.3.5 Takeda Recent Developments
  19. 7.4 Eisai
  20. 7.4.1 Eisai Company Information
  21. 7.4.2 Eisai Business Overview
  22. 7.4.3 Eisai Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio
  24. 7.4.5 Eisai Recent Developments
  25. 7.5 Guojian Pharmaceutical
  26. 7.5.1 Guojian Pharmaceutical Company Information
  27. 7.5.2 Guojian Pharmaceutical Business Overview
  28. 7.5.3 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio
  30. 7.5.5 Guojian Pharmaceutical Recent Developments
  31. 7.6 Celgen Pharm
  32. 7.6.1 Celgen Pharm Company Information
  33. 7.6.2 Celgen Pharm Business Overview
  34. 7.6.3 Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  36. 7.6.5 Celgen Pharm Recent Developments
  37. 7.7 Johson & Johson
  38. 7.7.1 Johson & Johson Company Information
  39. 7.7.2 Johson & Johson Business Overview
  40. 7.7.3 Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio
  42. 7.7.5 Johson & Johson Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Merck
  50. 7.9.1 Merck Company Information
  51. 7.9.2 Merck Business Overview
  52. 7.9.3 Merck Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck Ankylosing Spondylitis Treatment Drug Product Portfolio
  54. 7.9.5 Merck Recent Developments
  55. 7.10 Maibo Pharma
  56. 7.10.1 Maibo Pharma Company Information
  57. 7.10.2 Maibo Pharma Business Overview
  58. 7.10.3 Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio
  60. 7.10.5 Maibo Pharma Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Hisun Pharm
  68. 7.12.1 Hisun Pharm Company Information
  69. 7.12.2 Hisun Pharm Business Overview
  70. 7.12.3 Hisun Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
  72. 7.12.5 Hisun Pharm Recent Developments
  73. 7.13 Bio-Thera Solutions
  74. 7.13.1 Bio-Thera Solutions Company Information
  75. 7.13.2 Bio-Thera Solutions Business Overview
  76. 7.13.3 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio
  78. 7.13.5 Bio-Thera Solutions Recent Developments
  79. 7.14 Amgen
  80. 7.14.1 Amgen Company Information
  81. 7.14.2 Amgen Business Overview
  82. 7.14.3 Amgen Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio
  84. 7.14.5 Amgen Recent Developments
  85. 7.15 Abbive
  86. 7.15.1 Abbive Company Information
  87. 7.15.2 Abbive Business Overview
  88. 7.15.3 Abbive Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio
  90. 7.15.5 Abbive Recent Developments
  91. 7.16 Mitsubishi Tanabe
  92. 7.16.1 Mitsubishi Tanabe Company Information
  93. 7.16.2 Mitsubishi Tanabe Business Overview
  94. 7.16.3 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio
  96. 7.16.5 Mitsubishi Tanabe Recent Developments
8 North America
  1. 8.1 North America Ankylosing Spondylitis Treatment Drug Revenue (2021-2032)
  2. 8.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032)
  5. 8.3 North America Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032)
  9. 8.5 North America Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Ankylosing Spondylitis Treatment Drug Revenue by Country
  11. 8.6.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Ankylosing Spondylitis Treatment Drug Revenue (2021-2032)
  2. 9.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country
  11. 9.6.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Ankylosing Spondylitis Treatment Drug Revenue (2021-2032)
  2. 10.2 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032)
  5. 10.3 China Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032)
  9. 10.5 China Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ankylosing Spondylitis Treatment Drug Revenue (2021-2032)
  2. 11.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country
  11. 11.6.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue (2021-2032)
  2. 12.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country
  11. 12.6.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst